Holen Sie sich die Stockscreener-App
19.21
29.01%
4.32
Handel nachbörslich:
18.72
-0.49
-2.55%
Schlusskurs vom Vortag:
$14.89
Offen:
$15.16
24-Stunden-Volumen:
1.81M
Relative Volume:
3.61
Marktkapitalisierung:
$520.99M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-16.56
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
+57.33%
1M Leistung:
+39.40%
6M Leistung:
+17.06%
1J Leistung:
-2.34%
1-Tages-Spanne:
$15.15
$19.57
1-Wochen-Bereich:
$11.27
$19.57
52-Wochen-Spanne:
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
19.21 | 404.23M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday - Benzinga
Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen - MarketBeat
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - 富途牛牛
Mercury Systems Posts Better-Than-Expected Earnings,… - inkl
Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates - Investing.com Canada
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress - BioSpace
Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress - TipRanks
Arcturus Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
Transcript : Arcturus Therapeutics Holdings Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Arcturus Tightens Its Belt As Analysts Stay Bullish - Finimize
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcturus Therapeutics Q2 2025 results miss expectations - Investing.com
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Q2 net loss narrows - MarketScreener
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 By Investing.com - Investing.com Nigeria
Short interest data insights for Arcturus Therapeutics Holdings Inc.Historical Market Behavior and Trend Summary - Newser
Risk vs reward if holding onto Arcturus Therapeutics Holdings Inc.Swing Trade Timing with Daily Forecast - Newser
Multi factor analysis applied to Arcturus Therapeutics Holdings Inc.High Yield Signals with Entry Timing - Newser
Arcturus Therapeutics Q2 2025 Earnings Preview: Analysts Expect EPS of -$0.87, Revenue of $18.71M. - AInvest
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Arcturus Therapeutics Holdings Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings - GuruFocus
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Is Arcturus Therapeutics Holdings Inc. stock overvalued or undervaluedHigh-yield portfolio picks - Jammu Links News
What is the risk reward ratio of investing in Arcturus Therapeutics Holdings Inc. stockRapid return acceleration - Jammu Links News
How does Arcturus Therapeutics Holdings Inc. compare to its industry peersFree Risk Assessment Services - Jammu Links News
What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsBuild a winning investment portfolio - Jammu Links News
When is Arcturus Therapeutics Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
Is Arcturus Therapeutics Holdings Inc. a growth stock or a value stockGet professional guidance for market timing - Jammu Links News
What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Get alerts on high-potential stock breakouts - Jammu Links News
What drives Arcturus Therapeutics Holdings Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What is Arcturus Therapeutics Holdings Inc. company’s growth strategyTremendous financial leverage - Jammu Links News
What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversRapid return acceleration - Jammu Links News
Arcturus Therapeutics Holdings Inc expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Investors Don't See Light At End Of Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Tunnel - 富途牛牛
High Growth US Tech Stocks To Watch In August 2025 - simplywall.st
Can Arcturus Therapeutics Holdings Inc. hit a new high this monthWeekly Stock Opportunity Radar Scanner Activated - metal.it
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load? - simplywall.st
Why is Arcturus Therapeutics Holdings Inc. stock attracting strong analyst attentionBeginner Investor Report With Low Risk - Jammu Links News
Arcturus Therapeutics Holdings Inc. Sees Relief Buying After Extended DropValue Investing Picks With Stability Outlined - beatles.ru
Published on: 2025-07-29 23:05:26 - metal.it
Sector ETF Data Correlates with Strength in Arcturus Therapeutics Holdings Inc.Investment Playbook for Growing Markets Shared - metal.it
Using R and stats models for Arcturus Therapeutics Holdings Inc. forecastingFree Real-Time Analysis With Entry Targets - Newser
Price Floor Holding on Arcturus Therapeutics Holdings Inc. — Rebound PossibleSmart Investment Tips Gaining Popularity Among Analysts - metal.it
How Arcturus Therapeutics Holdings Inc. stock performs during market volatilityCapital Growth Summary Over Five Years - Newser
Arcturus Therapeutics Holdings Inc. Shows Risk Reward Favoring UpsideGrowth Focused Entry Plan Suggestions Issued - metal.it
Does Arcturus Therapeutics Holdings Inc. stock perform well during market downturnsFree Stock Market Real-Time Monitoring - Jammu Links News
Why Arcturus Therapeutics Holdings Inc. stock attracts strong analyst attentionTrading Volume Anomaly Summary and Insight - Newser
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):